November 30th 2023
A new survey finds that more people are using semaglutide and other GLP-1 therapies to lose less than 15 pounds.
Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
November 29th 2023
Adzynma is a recombinant protein designed to replace the deficient ADAMTS13 enzyme to treat patients with the rare hereditary blood clotting disorder congenital thrombotic thrombocytopenic purpura
November 24th 2023
A recent report predicts there could be an increase in premiums for Medicare Part D prescription drug plans in California, Florida, New York, Pennsylvania and Texas.
November 23rd 2023
A simulation study estimated the impact of biosimilar substitution on total cost of care and provider financial performance in the final performance period of the Oncology Care Model.
CMS Provides Temporary Code for New Multiple Myeloma Therapy
A permanent code is expected in the third quarter of 2021.
Prime Therapeutics Removes Intelence from Medicare Part D Formularies
The first generic equivalent of the HIV therapeutic is now available.
Movantik Chosen as Preferred Brand for Some Blue Cross Plans
The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.
CMS Begins Review of Aduhelm
The review will determine whether there should be a national Medicare coverage policy for the Alzheimer’s therapy.
Some Blues Plans Won’t Cover New Alzheimer’s Therapy Aduhelm
Commercial insurers are beginning to provide coverage information on Biogen’s controversial therapy.
Amber Specialty Pharmacy Chosen to Dispense Aduhelm
The specialty pharmacy is licensed in all 50 states.
PANTHERx Chosen as Pharmacy Provider for Exservan to treat ALS
Orally dissolving film formulation of riluzole is now available for patients who have difficulty swallowing.
FDA Approves Updated Label for Controversial Alzheimer’s Therapy
The prescribing information for Aduhelm now specifies its use in patients with a mild form of the disease.
Acerus Grabs Additional Formulary Status for Testosterone Brand
Coverage now includes 85% of commercial lives.
Acacia Pharma Expects to Meet Formulary Goals
Formulary adoption is a key step in achieving sales pull through starting in 2022, company officials said.
Cigna Moves Remicade Biosimilars to Preferred Formulary Status
Patients are being offered $500 to make the switch.
Biosimilar Insulin Glargine Led to Downward Trend in Pricing
A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.
Study: Medicare Drug Spending Lacks Understanding of Cost-effectiveness
Implementation of value-based approaches requires measurement of value, authors said.
Higher Drug Prices Can Lower Use of Recommended Therapies
Investigators looked at the association of antiparasitic drug prices with prescribing and prescription-filling behaviors and total outpatient treatment costs.
CMS Changes Coverage for CGM Devices
A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.
Consumers Across the Political Spectrum Want Lower Drug Prices, Poll Finds
Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.
Study Indicates Lorbrena not Cost-effective in Untreated NSCLC
Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.
Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
New Dry Eye Therapy Gains Formulary Coverage
Three commercial plans now cover the corticosteroid Eysuvis.
2 Clarke Drive Cranbury, NJ 08512